Chinese robot allows children with muscle disease to stand up for the first time
Vienna, June 4, 2026 - A medical exoskeleton is causing a sensation in China: thanks to a robot-assisted system, children and adolescents with spinal muscular atrophy (SMA) can stand upright and take their first steps for the first time in their lives. The technology comes from a company in Shenzhen and is already being used in several Chinese clinics.
A disease without a cure
Spinal muscular atrophy is a genetic disorder in which the nerve connections between the brain and muscles progressively degenerate. Affected individuals gradually lose the ability to tense their muscles. Depending on the severity, patients are reliant on a wheelchair or are completely bedridden. In severe cases, the disease also affects swallowing and breathing. An estimated 300,000 to 400,000 people worldwide live with SMA. In Austria, approximately 400 people are affected. Drug therapies such as Spinraza or Zolgensma can slow the course of the disease, but cost up to two million euros per treatment.
How the exoskeleton works
The Chinese robot system encloses the patient's legs and torso and takes over muscle work through electric motors. Sensors detect the slightest movement impulses and translate them into coordinated movements. According to reports from the South China Morning Post, several young patients in rehabilitation centers in Guangdong Province were able to stand up for the first time without assistance. Some took their very first steps. The emotional reactions of the families were shared millions of times on social media. Technically, the system fits into China's growing medical robotics industry. Shenzhen has established itself as a hub for medical device development, in addition to electronics manufacturing.
Relevance for Austria and Europe
For European healthcare systems, the question arises whether such technologies could be imported or manufactured under license in the future. The EU Medical Device Regulation sets high approval hurdles, which has so far delayed the market entry of Chinese medical devices. At the same time, Austrian health insurers are struggling with the enormous costs of SMA gene therapies. An exoskeleton that enables mobility without treating the underlying disease could represent a supplementary option. The price of the Chinese system has not yet been released.
The Two Sides of Power
China's advancements in medical robotics deserve recognition. For families whose children are taking their first steps, the technology is life-changing. At the same time, questions remain: how sustainable is the therapeutic benefit? Do the clinical studies meet Western standards? And what about data protection when sensors capture bodily data? The success stories in Chinese media also serve the state narrative of technological advancement. For Austrian patients and doctors, it is important to distinguish between genuine medical breakthroughs and PR staging. If the system were to be independently validated, it could nevertheless make a valuable contribution.
Source: China – South China Morning Post | Original Article
